AbCellera Biologics Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 6.6 million compared to USD 101.38 million a year ago. Net loss was USD 28.61 million compared to net income of USD 26.62 million a year ago. Basic loss per share from continuing operations was USD 0.1 compared to basic earnings per share from continuing operations of USD 0.09 a year ago. Diluted loss per share from continuing operations was USD 0.1 compared to diluted earnings per share from continuing operations of USD 0.08 a year ago.
For the nine months, revenue was USD 28.85 million compared to USD 463.88 million a year ago. Net loss was USD 99.25 million compared to net income of USD 188.41 million a year ago. Basic loss per share from continuing operations was USD 0.34 compared to basic earnings per share from continuing operations of USD 0.66 a year ago. Diluted loss per share from continuing operations was USD 0.34 compared to diluted earnings per share from continuing operations of USD 0.6 a year ago.